Asieris Pharmaceuticals Website, Blog & Press Pages

Asieris Pharmaceuticals Website, Blog & Press Pages - aVenture

Asieris Pharmaceuticals - Library

asieris.comCrawled Oct 16, 2026

Product

1 page

Products/products
The pipeline lists APL-1702 (CEVIRA), a photodynamic drug-device combination product for cervical high-grade squamous intraepithelial lesions (CIN2), with NMPA approval in China and marketing review and approval in Europe.

Press

2 pages

Media/media
Yahong Pharmaceuticals says website content is copyrighted or otherwise authorized for use and must be used in accordance with the Copyright Law of the People’s Republic of China and other relevant laws.
News/news

About

1 page

About/about
Asieris Pharmaceuticals was founded in 2010 and develops drugs for genitourinary tumors and related diseases. APL-1202 received NMPA approval for an innovative drug clinical trial.

Contact

1 page

Contact/contact
Asieris USA 201 King of Prussia Rd., Suite 650 Radnor, PA 19087, USA 2460 Embarcadero Way, Suite B Palo Alto, CA 94303 Partnership bd@asieris.com Investor Relations investor@asieris.com Media Contact pr@asieris.com Medical Inquiries medinfo@asieris.com Adverse Event Reporting drugsafety@asieris.com

Homepage

1 page

Homepage/
The page lists Vesique (APL-1202) and Cevira (APL-1702) and identifies urologic oncology, women’s health, and breast and gynecologic oncology as core areas.

Privacy

1 page

Privacy Policy/privacy-policy
Asieris Pharmaceuticals says it respects privacy and presents a Privacy Policy for personal information submitted through the website.

Coverage

5 items

Asieris Pharmaceuticals Releases 2025 Annual Report: Flagship Product Approval Marks Inflection Point; Commercialization 2.0 Drives Growthasieris.com
Asieris Pharmaceuticals releases its 2025 annual report, describing approval of its flagship product as an inflection point for the company. The report says its Commercialization 2.0 effort drives growth and highlights revenue momentum and an advancing pipeline.
Apr 2026 · Asieris PharmaceuticalsNews article
Asieris CEVIRA Approved in China as First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesionsprnewswire.com/news-releases/asieris-cevira-approved-in-china-as-first-in-class-non-invasive-therapy-for-cervical-precancerous-lesions-302702283.html
Asieris announced that China’s National Medical Products Administration (NMPA) approved Cevira (APL-1702) as a first-in-class, non-invasive therapy for cervical precancerous lesions (CIN2). The approval enables commercial launch in China.
Mar 2026 · PR Newswire / AsierisNews article
Asieris Announces European Medicines Agency Accepts Marketing Authorization Application for APL-1702asieris.com/asieris-announces-european-medicines-agency-accepts-marketing-authorization-application-for-apl-1702/
Asieris announced that the European Medicines Agency accepted a marketing authorization application for APL-1702 (CEVIRA), for high-grade squamous intraepithelial lesions (HSIL). The company describes the acceptance as a major milestone for the global expansion of non-invasive cervical therapy.
Feb 2026 · Asieris PharmaceuticalsNews article
Qiming's Portfolio Company Asieris Pharmaceuticals Lands on STAR Marketqimingvc.com/en/news/qiming%E2%80%99s-portfolio-company-asieris-pharmaceuticals-lands-star-market
Asieris Pharmaceuticals (SHSE: 688176) lists on the Shanghai STAR Market, marking the first IPO in Qiming Venture Partners’ 2022 portfolio. Qiming led the pharmaceutical company’s Series D financing round in 2020.
Jan 2022 · Qiming Venture PartnersNews article